The corporation just lately announced that its Stage 2b scientific trial of its picked five-MeO-copyright solution prospect, GH001, in individuals with procedure-resistant depression and its Period 2a clinical trial of GH001 in postpartum melancholy are on track for anticipated completion in Q3 2024.In a single of Compass’ most just lately reveal